13226 related articles for article (PubMed ID: 10890377)
1. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
4. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
[TBL] [Abstract][Full Text] [Related]
8. S-100beta and MIA in advanced melanoma in relation to prognostic factors.
Auge JM; Molina R; Filella X; Bosch E; Gonzalez Cao M; Puig S; Malvehy J; Castel T; Ballesta AM
Anticancer Res; 2005; 25(3A):1779-82. PubMed ID: 16033099
[TBL] [Abstract][Full Text] [Related]
9. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
[TBL] [Abstract][Full Text] [Related]
12. S100 serum level: a tumour marker for metastatic melanoma.
Bottoni U; Izzo P; Richetta A; Mannooranparampil TJ; Devirgiliis V; Del Giudice M; Reale MG; Frati L; Calvieri S
Melanoma Res; 2003 Aug; 13(4):427-9. PubMed ID: 12883371
[No Abstract] [Full Text] [Related]
13. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients.
Smit LH; Korse CM; Hart AA; Bonfrer JM; Haanen JB; Kerst JM; Nieweg OE; de Gast GC
Eur J Cancer; 2005 Feb; 41(3):386-92. PubMed ID: 15691637
[TBL] [Abstract][Full Text] [Related]
14. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
16. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1).
Barak V; Kaiserman I; Frenkel S; Hendler K; Kalickman I; Pe'er J
Anticancer Res; 2011 Jan; 31(1):345-9. PubMed ID: 21273622
[TBL] [Abstract][Full Text] [Related]
17. Analysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph node metastases--a prospective study in 231 patients.
Neuss H; Koplin G; Raue W; Reetz C; Mall JW
Acta Chir Belg; 2011; 111(4):214-8. PubMed ID: 21954736
[TBL] [Abstract][Full Text] [Related]
18. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma.
Bolander A; Agnarsdóttir M; Wagenius G; Strömberg S; Pontén F; Ekman S; Brattström D; Larsson A; Einarsson R; Ullenhag G; Hesselius P; Bergqvist M
Melanoma Res; 2008 Dec; 18(6):412-9. PubMed ID: 19011512
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of beta1 integrin expression in metastatic melanoma.
Vihinen P; Nikkola J; Vlaykova T; Hahka-Kemppinen M; Talve L; Heino J; Pyrhönen S
Melanoma Res; 2000 Jun; 10(3):243-51. PubMed ID: 10890378
[TBL] [Abstract][Full Text] [Related]
20. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma.
Vihinen PP; Hilli J; Vuoristo MS; Syrjänen KJ; Kähäri VM; Pyrhönen SO
Acta Oncol; 2007; 46(5):678-84. PubMed ID: 17562445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
